Massive study probes cancer risk of common diabetes drug

NCT ID NCT02695121

Completed Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study analyzed health records from over 2 million people with type 2 diabetes to see if those taking dapagliflozin had a different risk of breast or bladder cancer compared to those on other diabetes medications. Researchers tracked cancer diagnoses for up to 12 years. The goal is to better understand the long-term safety of dapagliflozin.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dapagliflozin
What this could lead to: If this study finds no increased cancer risk, it could reassure patients and doctors that dapagliflozin is safe to use for type 2 diabetes.
What could go wrong: This is an observational study, not a controlled trial, so it can only show links, not cause and effect. Results may be influenced by other factors like patient health or lifestyle.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm type 2 diabetes mellitus urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER BREAST CANCER

Contacts and locations

Locations

Research Site

Wilmington, Delaware, United States
Research Site

Washington D.C., District of Columbia, United States
Research Site

Utrecht, Netherlands
Research Site

London, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.